NLRP3 and gastric cancer: Besides, Huang et al. reported that in gastric cancer cells, famotidine, a gastric antisecretory drug, could promote the activation of NLRP3 inflammasomes by upregulating expression of NLRP3, ASC, and Caspase-1, then enhance IL-18, not IL-1β, mature and secretion, thus trigger cell pyroptosis and aggravate inflammation, which was considered to be critical in development of gastric cancer (Huang et al., 2021).